Vivesto

0,239

SEK

-2,85 %

Mindre end 1K følgere

VIVE

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Finansielt overblik og estimater

Ownership

-2,85%

+2,36%

-17,59%

-8,95%

-4,97%

-24,13%

-85,22%

-96,88%

-98,68%

Vivesto is a pharmaceutical company focused on developing innovative treatments for serious diseases in oncology. The company researches new therapies that can improve patient outcomes and quality of life. The company operates globally with a primary presence in Europe and North America. Vivesto was founded in 1999 and is headquartered in Uppsala, Sweden.

Markedsværdi

128,59 mio. SEK

Aktieomsætning

107,84 t SEK

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Finanskalender

8.5

2025

Generalforsamling '25

8.5

2025

Delårsrapport Q1'25

12.8

2025

Delårsrapport Q2'25

ViserAlle indholdstyper

Pressemeddelelse20.2.2025, 16.10

Carnegie Access: Vivesto: Intervju – Statusuppdatering efter Q4 2024-rapporten

Pressemeddelelse16.1.2025, 13.00

Vivesto receives approval to initiate a dose-finding study of Paccal Vet in cats

Pressemeddelelse19.12.2024, 10.00

Vivesto strengthens Cantrixil program with new preclinical results and patent application

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Pressemeddelelse11.11.2024, 10.33

Vivesto’s Paccal Vet receives Limited Market classification in EU

Selskabsmeddelelse7.11.2024, 09.54

Vivesto signs Apealea option agreement with Zhida Pharmaceutical

Pressemeddelelse1.7.2024, 06.00

Vivesto receives positive Cantrixil preclinical efficacy data

Selskabsmeddelelse23.5.2024, 08.48

Report from Annual General Meeting in Vivesto AB

Selskabsmeddelelse23.4.2024, 06.00

Notice of Annual General Meeting in Vivesto AB

Pressemeddelelse19.3.2024, 12.06

Vivesto to hold live-streamed Paccal Vet R&D Update on March 26

Selskabsmeddelelse7.3.2024, 07.10

Vivesto doses first patient in its clinical Paccal Vet trial

Pressemeddelelse30.1.2024, 07.00

Vivesto's international patent application for XR-18 receives positive decision

Pressemeddelelse28.12.2023, 07.00

Vivesto’s US clinical Paccal Vet trial receives approval to start patient recruitment

Selskabsmeddelelse22.12.2023, 16.26

Vivesto’s Paccal Vet granted FDA MUMS designation

Selskabsmeddelelse22.12.2023, 15.28

Vivesto makes impairment charge following withdrawal of European market authorizations for Apealea

Pressemeddelelse19.12.2023, 11.28

Vivesto reports positive preclinical data supporting continued development of Cantrixil

Selskabsmeddelelse23.11.2023, 20.11

Nomination Committee appointed for the 2024 Annual General Meeting in Vivesto

Selskabsmeddelelse23.11.2023, 06.30

Vivesto and Elevar sign agreement ending Apealea® partnership

Selskabsmeddelelse16.11.2023, 07.00

Interim report for the period January 1, 2023 – September 30, 2023

Selskabsmeddelelse25.10.2023, 05.30

Vivesto focuses its project portfolio and introduces cost-saving measures

Selskabsmeddelelse15.9.2023, 19.19

Delisting of Vivesto’s shares from Frankfurt Stock Exchange effective as of 15 September 2023

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.